Adaptive Biotechnologies Stock Analysis

Adaptive biotechnologies stock analysis This compares to loss of $0.27 per share a year ago. Their forecasts range from $52.00 to $74.00. Adaptive biotechnologies has been rated by cowen , and william blair in the past 90 days. On average, they expect adaptive biotechnologies' stock price to reach $60.33 in the next year. Adaptive biotechnologies currently has 2 hold ratings and 3 buy ratings from wall street analysts. Summary of all time highs, changes and price drops for adaptive biotechnologies; What analysts cover adaptive biotechnologies? For the last reported quarter, it was expected that adaptive biotechnologies would post a loss of $0.43 per share when it actually produced a. Quote stock analysis news price vs fair value sustainability trailing returns. Adpt | complete adaptive biotechnologies corp.

Nasdaq Adpt End Of Day And Historical Stock Data Adaptive Biotechnologies Corp

Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That average rating earns adpt an analyst ranking of 59, which means it ranks higher than 59 of stocks, based on data compiled by investorsobserver. Investors in adaptive biotechnologies corporation (nasdaq:adpt) have tasted that bitter downside in the last year, as the share price. Stock chart stock analysis is a method for investors and traders to make buying and selling decisions. And make sure their analysis is clear and in no way misleading or deceptive Adaptive biotechnologies (adpt) came out with a quarterly loss of $0.40 per share versus the zacks consensus estimate of a loss of $0.43.

Adaptive biotechnologies stock analysis. See our latest analysis for adaptive biotechnologies. The company offers immunoseq research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; Analyst estimates, including adpt earnings per share estimates and analyst recommendations. Its clinical diagnostic product, clonoseq, is test authorized by the fda for the detection and monitoring of minimal residual. Find the latest adaptive biotechnologies corpor (adpt) stock quote, history, news and other vital information to help you with your stock trading and investing. Investorsobserver gives adaptive biotechnologies corp (adpt) an overall rank of 37, which is below average. 5 brokers have issued 1 year target prices for adaptive biotechnologies' shares. Adaptive biotechnologies isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Adpt stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Despite the fact that adaptive biotechnologies corporation (nasdaq:adpt) stock rose 3.9% last week, insiders who sold us$229k worth of stock in the previous 12 months are likely to be better off. The stock has a consensus analyst rating of buy. a buy rating indicates that analysts believe adpt will outperform the market and that investors should add to their positions of adaptive biotechnologies. Adaptive biotechnologies corp has a market cap of $4753661130. Analysts who follow adaptive biotechnologies corp on average expect it to climb 84.79% over the next twelve months. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading. Adaptive biotechnologies corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Here's why adaptive biotechnologies rose 31.9% in. Adaptive biotechnologies corporation (adpt) saw an uptrend of 4.90% in the recent trading with $39.82 being its most recent. The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares. This suggests a possible upside of 127.6% from the stock's current price. Those same analysts give the stock an average rating of strong buy. Adpt stock analysis overview what this means:

Analysts Estimate Adaptive Biotechnologies Adpt To Report A Decline In Earnings What To Look Out For Nasdaq

Goldman Sachs These 2 Stocks Are Poised To Surge By At Least 30

Adaptive Biotechnologies Corp Shares Close In On 52-week Low - Market Mover Nasdaq

Hot Tech Stock To Watch Adaptive Biotechnologies Corp Nasdaq Adpt Biotechnology Nasdaq Tech Stocks

Adaptive Biotechnologies Stock Quote Adpt - Stock Price News Charts Message Board Trades

Adaptive Biotechnologies Nasdaqadpt Stock Price News Charts - Benzinga

Aapl Stock Chart Stochastic Oscillator Candlestick Chart Chart Stock Charts